Abstract
The effect of SCH 1000 and isoproterenol was evaluated in 10 patients with extrinsic asthma. The onset of action for the SCH 1000 dose compared to the baseline response occurred at or before 15 minutes (FEV 1 and MEFR). The onset of action for the isoproterenol dose occurred at or before one minute for all three pulmonary function variables. At the 1, 3, 6 and 15 minute intervals the response to the isoproterenol dose was significantly greater than the response to the SCH 1000 dose for FEV 1, FVC and MEFR. At 30 and 60 minutes, however, the response to SCH 1000 was progressively increasing, whereas the response to isoproterenol was decreasing. The maximum improvement in FEV 1 for isoproterenol was 49% at three and six minutes, whereas for SCH 1000 was 28% at 60 minutes. In patients with chronic bronchitis or bronchial asthma SCH 1000 may be considered as a therapeutic alternative to beta adrenergic bronchodilators and in patients who also have cardiac arrhythmias or angina pectoris and are adversely affected by sympathomimetic drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 223-230 |
| Number of pages | 8 |
| Journal | Annals of Allergy |
| Volume | 36 |
| Issue number | 4 |
| State | Published - 1976 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
Cite this
Comparison of the bronchodilating effects of SCH 1000 with isoproterenol in patients with bronchial asthma. / Vlagopoulos, T.; Townley, R. G.; Ghazanshahi, S.; Bewtra, Againdra K.; Burke, K.
In: Annals of Allergy, Vol. 36, No. 4, 1976, p. 223-230.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Comparison of the bronchodilating effects of SCH 1000 with isoproterenol in patients with bronchial asthma
AU - Vlagopoulos, T.
AU - Townley, R. G.
AU - Ghazanshahi, S.
AU - Bewtra, Againdra K.
AU - Burke, K.
PY - 1976
Y1 - 1976
N2 - The effect of SCH 1000 and isoproterenol was evaluated in 10 patients with extrinsic asthma. The onset of action for the SCH 1000 dose compared to the baseline response occurred at or before 15 minutes (FEV 1 and MEFR). The onset of action for the isoproterenol dose occurred at or before one minute for all three pulmonary function variables. At the 1, 3, 6 and 15 minute intervals the response to the isoproterenol dose was significantly greater than the response to the SCH 1000 dose for FEV 1, FVC and MEFR. At 30 and 60 minutes, however, the response to SCH 1000 was progressively increasing, whereas the response to isoproterenol was decreasing. The maximum improvement in FEV 1 for isoproterenol was 49% at three and six minutes, whereas for SCH 1000 was 28% at 60 minutes. In patients with chronic bronchitis or bronchial asthma SCH 1000 may be considered as a therapeutic alternative to beta adrenergic bronchodilators and in patients who also have cardiac arrhythmias or angina pectoris and are adversely affected by sympathomimetic drugs.
AB - The effect of SCH 1000 and isoproterenol was evaluated in 10 patients with extrinsic asthma. The onset of action for the SCH 1000 dose compared to the baseline response occurred at or before 15 minutes (FEV 1 and MEFR). The onset of action for the isoproterenol dose occurred at or before one minute for all three pulmonary function variables. At the 1, 3, 6 and 15 minute intervals the response to the isoproterenol dose was significantly greater than the response to the SCH 1000 dose for FEV 1, FVC and MEFR. At 30 and 60 minutes, however, the response to SCH 1000 was progressively increasing, whereas the response to isoproterenol was decreasing. The maximum improvement in FEV 1 for isoproterenol was 49% at three and six minutes, whereas for SCH 1000 was 28% at 60 minutes. In patients with chronic bronchitis or bronchial asthma SCH 1000 may be considered as a therapeutic alternative to beta adrenergic bronchodilators and in patients who also have cardiac arrhythmias or angina pectoris and are adversely affected by sympathomimetic drugs.
UR - http://www.scopus.com/inward/record.url?scp=0017289875&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0017289875&partnerID=8YFLogxK
M3 - Article
VL - 36
SP - 223
EP - 230
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
SN - 1081-1206
IS - 4
ER -